GBA: Wider regulation = wider implications

Tiny variations our DNA can have a significant impact on our lives. For the last 20 years, Parkinson’s researchers have been collecting data highlighting ‘genetic risk factors’ that are associated with increasing one’s risk of developing the condition. More recently, however, these same scientists have started shifting their attention to the […]


PDCORE

Assessing the progression of Parkinson’s is a very difficult task, but accurately doing so is critical to our ability to evaluate the disease modifying potential of new therapies. The clinical measures currently used in clinical trials have been developed using large longitudinal studies that assessed individuals over long periods of time. […]


MAMS the word

The way that clinical trials are conducted doesn’t make much sense. They take too long and a lot of resources to set up, they take a long time to be conducted, and we have to wait until they are finished before we get the results. And then on top of that […]


The Ambroxol Results

  The new year has started with some pleasing clinical trial news for the Parkinson’s community: The results of the “Ambroxol in Disease Modification in Parkinson Disease” (AiM-PD study) have been published. This is a clinically available drug that is used for the treatment of respiratory issues, which researchers are re-purposing for Parkinson’s based on […]


An exercise in expectations: Exenatide III

  In August 2017, the results of a Phase II double-blind, placebo controlled clinical trial investigating whether the diabetes drug Exenatide (aka Bydureon) can be repurposed for the treatment of Parkinson’s were published. Despite the fact that the study did not meet most of its end points, the Parkinson’s community got very excited about one […]